Bayer's Lynkuet shows improved self-reported sleep in post hoc trial analysis
- Bayer presented a new exploratory analysis of Lynkuet’s sleep-related outcomes at the 2026 Menopause Society Annual Meeting.
- Pooled OASIS-1 and OASIS-2 trial data showed greater self-reported sleep improvements with Lynkuet than placebo in women with menopause-related hot flashes.
- The post hoc analysis lacked formal statistical testing of differences between treatment groups.
- Lynkuet is FDA-approved to treat moderate to severe hot flashes due to menopause.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202610261600BIZWIRE_USPR_____20261026_BW682997) on October 26, 2026, and is solely responsible for the information contained therein.